Catalent, Inc. with ticker code (CTLT) now have 8 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between $63.50 and $42.00 suggesting an average Analsyt target price of $60.75. Given that the stocks previous close was at $59.92 and the analysts are correct then we can expect a percentage increase in value of 1.4%. The 50 day MA is $59.98 and the 200 day moving average is $57.62. The market cap for the company is 10.78B. The stock price is currently at: $59.41 USD
The potential market cap would be $10,933,000,976 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $24.40 and a -0.18% return on assets.
Catalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Its Biologics segment provides development and manufacturing for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene therapies. Its Softgel and Oral Technologies segment provide formulation, development, and manufacturing services for soft capsules, as well as large-scale manufacturing of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. Its Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for, drugs, biologics and clinical trials.
